Early access to medicines with added therapeutic value
Measuring and comparing time to medicines access in England, France, Germany, Italy and Spain
Bibliographic Data
| ID | 21467535 |
|---|---|
| Authors | Sophie Delcroix-Lopes (l'Assurance Maladie), Nadia Mohamad Amer (Scientific Research Institute of Healthcare Organization and Medical Management), Nadia Amer, C Chaignot (0000-0002-1477-9401, Institut de Relations Internationales et Stratégiques), Charlotte Pelletan (Institut de Relations Internationales et Stratégiques) |
| Year | 2025 |
| Volume | 157 |
| Pages | 105317 |
| Publication date | 2025-07-01 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Health Policy (JOURNAL) |
| Journal identifiers | ISSN: 0168-8510 • E-ISSN: 1872-6054 |
| Publisher | Elsevier BV (PUBLISHER) |
| DOI | 10.1016/j.healthpol.2025.105317 |
| PMID | 40300221 |
| OpenAlex | W4409872402 |
| Language | EN |
| References cited | 11 |
The scientific breakthroughs over the past few decades have opened up new therapeutic possibilities, transforming the treatment of critical illnesses like cancer and rare diseases. However, delayed access to these innovations can lead to a loss of valuable life years for patients. The annual European medicines access times Monitor, launched by the French Statutory Health Insurance (CNAM) with the support of the French National Authority for Health (HAS), analysed time to patient access across five countries between 2017 and 2023 (England, France, Germany, Italy and Spain) for a sample of 50 molecules that demonstrate therapeutic improvement. The results underscore the crucial role of Early Access Schemes-EAS in accelerating patient access to medicines. These schemes are particularly prevalent in countries where national reimbursement is contingent on Health Technology Assessment-HTA assessments and price negotiations-notably France, Italy, and Spain. These findings indicate that early access schemes, rather than being restricted to compassionate use for patients with no alternative treatment options, can also serve as a strategy to expedite access to essential therapies, particularly cancer drugs, prior to their formal reimbursement
Access to medicines · Geography · Public health · Sociology · Demography · Health Systems, Economic Evaluations, Quality of Life · Medicine · Nursing · Pharmaceutical Economics and Policy · Pharmaceutical studies and practices
| Highly cited | No |
|---|